Article
Cell Biology
Qinglin Li, Wenju Mo, Yuqin Ding, Xiaowen Ding
Summary: The study showed that lncRNA TPA can affect breast cancer EMT through the TGF-beta signaling pathway, thereby promoting invasion and metastasis of breast cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Qinglin Li, Wenju Mo, Yuqin Ding, Xiaowen Ding
Summary: The study demonstrated that lncRNA TPA affects breast cancer EMT through the TGF-beta signaling pathway, leading to increased invasion and metastasis of breast cancer cells. It is suggested that lncRNA TPA may influence corresponding signaling pathways through interacting proteins, thereby promoting breast cancer invasion and metastasis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Milene N. O. Moritz, Alyssa R. Merkel, Ean G. Feldman, Heloisa S. Selistre-de-Araujo, Julie A. Rhoades (Sterling)
Summary: The expression of α2β1 integrin is inversely correlated with bone metastatic potential in breast cancer. Overexpression of the α2 integrin subunit increases primary tumor growth and dissemination to bone, with no impact on tumor establishment and bone destruction.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Wen-Kai Shi, Qiao-Li Shang, Yong-Fu Zhao
Summary: This study investigates the role of SPC25 in promoting hepatocellular carcinoma (HCC) progression. It is found that SPC25 is highly expressed in HCC and associated with poor prognosis and metastasis. Silencing SPC25 inhibits invasion and migration of HCC cells in vitro and in vivo. The study also reveals that SPC25 affects genes associated with extracellular matrix-integrin interactions, and upregulation of ITGB4 partially reverses the decline in cell invasion and migration capacities caused by SPC25 silencing. Blocking both SPC25 and ITGB4 reduces phosphorylation of downstream elements in the integrin pathway. Overall, this research highlights the important role of SPC25 as both a prognostic indicator and a promoter of metastasis in HCC.
Article
Oncology
Qi Lu, Li Wang, Yabiao Gao, Ping Zhu, Luying Li, Xue Wang, Youping Jin, Xiuling Zhi, Jerry Yu, Xin Li, Xingjun Qin, Ping Zhou
Summary: The study revealed that lncRNA APOC1P1-3 promotes breast cancer metastasis by regulating apoptosis and anoikis resistance-related protein expression. It acts as a sponge to block the inhibition of Bcl-2 by specifically binding to miRNA-188-3p.
CANCER CELL INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Yunxiang Zhang, Xiaotong Dong, Xiangyu Guo, Chunsen Li, Yanping Fan, Pengju Liu, Dawei Yuan, Xialin Ma, Jingru Wang, Jie Zheng, Hongli Li, Peng Gao
Summary: It was found that lncRNA BC069792 is down-regulated in breast cancer tissues and decreases significantly in breast cancer with high pathological grade, lymph node metastasis, and high Ki-67 index. BC069792 acts as a molecular sponge to adsorb hsa-miR-658 and hsa-miR-4739, up-regulates the protein expression of Potassium Voltage-Gated Channel Q4 (KCNQ4), inhibits JAK2 and p-AKT activities, and thus suppresses breast cancer growth in vitro and in vivo.
Article
Chemistry, Applied
Suresh Sulekha Dhanisha, Sudarsanan Drishya, Chandrasekharan Guruvayoorappan
Summary: In this study, macrophage membrane-coated liposome-based biomimetic nanoparticles were developed to improve the in vivo bioavailability of Naringenin (NG). The nanoparticles exhibited good biocompatibility, stability, and pH-responsive drug release kinetics, leading to higher cellular uptake in vitro. The anti-metastatic efficacy of NG-loaded biomimetic nanoparticles was confirmed in experimental models, indicating its potential for reducing metastatic colonies in the lungs.
Article
Biochemical Research Methods
Martina Crippa, Simone Bersini, Mara Gilardi, Chiara Arrigoni, Sara Gamba, Anna Falanga, Christian Candrian, Gabriele Dubini, Marco Vanoni, Matteo Moretti
Summary: The presence of platelets and neutrophils in the early metastatic niche significantly enhances cancer cell transendothelial migration. Using an antiplatelet drug can reduce the expression of EMT markers in cancer cells and impair their ability to extravasate, providing new insights for clinical treatment.
Article
Biotechnology & Applied Microbiology
Ting-Chih Yeh, Neng-Yu Lin, Chin-Yu Chiu, Tzu-Wen Hsu, Hsin-Yi Wu, Hsuan-Yu Lin, Chi-Hau Chen, Min-Chuan Huang
Summary: Ovarian cancer is a deadly gynecological malignancy with peritoneal metastasis. TMTC1, an O-mannosyltransferase, is highly expressed in ovarian cancer and its role remains unclear. High TMTC1 expression in ovarian cancer tissues was associated with poor prognosis. Silencing TMTC1 reduced cancer cell viability, migration, invasion, and peritoneal tumor growth and metastasis. TMTC1 overexpression promoted malignant properties. Integrins beta 1 and beta 4 were identified as O-mannosylated protein substrates of TMTC1, and knockdown of these integrins reversed TMTC1-mediated cell migration and invasion. TMTC1 could be a potential therapeutic target for ovarian cancer.
CANCER GENE THERAPY
(2023)
Article
Medicine, Research & Experimental
Bingjie Zhou, Min Li, Xiaomin Xu, Lan Yang, Meiling Ye, Yan Chen, Jiayi Peng, Linyu Xiao, Luyao Wang, Shiqi Huang, Ling Zhang, Qing Lin, Zhirong Zhang
Summary: The DGEA-Lipo-DOX platform demonstrated improved antitumor ability in breast cancer treatment through enhanced blood circulation and drug accumulation at tumor sites. Targeting integrin alpha(2)beta(1) by DGEA may represent a potentially safer alternative therapeutic strategy for breast cancer treatment.
MOLECULAR PHARMACEUTICS
(2021)
Article
Multidisciplinary Sciences
Anjan K. Pradhan, Santanu Maji, Praveen Bhoopathi, Sarmistha Talukdar, Padmanabhan Mannangatti, Chunqing Guo, Xiang-Yang Wang, Lorraine Colon Cartagena, Michael Idowu, Joseph W. Landry, Devanand Sarkar, Luni Emdad, Webster K. Cavenee, Swadesh K. Das, Paul B. Fisher
Summary: MDA-9/Syntenin is a highly conserved PDZ-domain scaffold protein with elevated expression in advanced stages of melanoma. Knockdown of MDA-9/Syntenin decreases cancer cell metastasis and sensitizes cells to radiation. Additionally, treatment with a pharmacological inhibitor of the PDZ1 domain activates the immune system to kill cancer cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biology
Qing Ma, Liuyi Yang, Karen Tolentino, Guiping Wang, Yang Zhao, Ulrike M. Litzenburger, Quanming Shi, Lin Zhu, Chen Yang, Huiyuan Jiao, Feng Zhang, Rui Li, Miao-Chih Tsai, Jun-An Chen, Ian Lai, Hong Zeng, Lingjie Li, Howard Y. Chang
Summary: This study demonstrates the significant role of human HOTAIR lncRNA in promoting breast cancer progression, including increased metastatic capacity and invasiveness in breast cancer cells, and alterations in the transcriptome and chromatin accessibility landscape.
Article
Oncology
Jiabao Zhou, Jennifer M. Down, Christopher N. George, Jessica Murphy, Diane Lefley, Claudia Tulotta, Marwa A. Alsharif, Michael Leach, Penelope D. Ottewell
Summary: Breast cancer bone metastasis is currently incurable. Inhibition of IL-1 signaling has shown potential in preventing metastasis and reducing breast cancer growth in the bone. However, existing drugs targeting IL-1 signaling have side effects of promoting primary tumor growth. This study investigates the potential of targeting other members of the IL-1 pathway to reduce bone metastasis without increasing tumor growth outside of the bone.
Article
Cell Biology
Daniel Xin Zhang, Xuan T. T. Dang, Luyen Tien Vu, Claudine Ming Hui Lim, Eric Yew Meng Yeo, Brenda Wan Shing Lam, Sai Mun Leong, Noorjehan Omar, Thomas Choudary Putti, Yu Chen Yeh, Victor Ma, Jia-Yuan Luo, William C. Cho, Gang Chen, Victor Kwan Min Lee, Andrew Grimson, Minh T. N. Le
Summary: Breast cancer cells release extracellular vesicles (EVs) that contain a large amount of biocargo, promoting intercellular communication and metastasis. It has been found that highly metastatic breast cancer cells have a higher enrichment of integrins, particularly alpha v and beta 1 subunits, in their EVs compared to poorly metastatic cells. Integrin alpha v has also been associated with disease progression in breast cancer patients. The export of integrin alpha v beta 1 into EVs is facilitated by members of the galectin family. Inhibition of the integrin alpha v beta 1 complex reduces the binding of EVs to fibronectin and decreases the metastatic potential of breast cancer cells.
JOURNAL OF EXTRACELLULAR VESICLES
(2022)
Article
Cell Biology
Sophie Ayama-Canden, Rodolfo Tondo, Martha Liliana Pineros Leyton, Noelle Ninane, Catherine Demazy, Marc Dieu, Antoine Fattaccioli, Aude Sauvage, Tijani Tabarrant, Stephane Lucas, Davide Bonifazi, Carine Michiels
Summary: Metastasis is the leading cause of mortality in breast cancer, especially in triple negative breast cancer. The extracellular matrix, specifically the IGDQ motif in fibronectin, plays a significant role in regulating cell migration before metastasis formation. SRSF6 is identified as a potential master regulator of cell migration and integrin trafficking, with Indacaterol showing potential as a therapy to prevent cell migration and reduce metastasis formation in breast cancer.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Biotechnology & Applied Microbiology
Haiying Wang, Liqian Yang, Minghui Liu, Jianyuan Luo
Summary: Posttranslational modifications (PTMs) of proteins play important roles in regulating cellular physiological and pathological processes. New modifications like succinylation, hydroxybutyrylation, and lactylation introduce a new layer to protein regulation with wide application prospects.
CANCER GENE THERAPY
(2023)
Article
Oncology
Liangyi Zhu, Ying Yang, Haishuang Li, Luzheng Xu, Huanyu You, Yantao Liu, Zongran Liu, Xiaodan Liu, Danfeng Zheng, Juntao Bie, Jiaqi Li, Chao Song, Bao Yang, Jianyuan Luo, Qing Chang
Summary: This study explores the mechanism of tumor-associated microglia/macrophages (TAMs) activation/polarization in sonic hedgehog subgroup medulloblastoma (SHH-MB). M2-like macrophages were found to be enriched in SHH-MBs, and their polarization can be induced by SHH MB-derived exosomes. Downregulated let-7i-5p and miR-221-3p were identified as regulators of TAM polarization via upregulating peroxisome proliferator activated receptor gamma (PPAR gamma). The PPAR gamma antagonist improved the antitumor activity of SMO inhibitor by inhibiting M2-like TAMs. These findings suggest a potential immunotherapeutic strategy for SHH-MB.
Article
Biochemistry & Molecular Biology
Jiaojiao Zheng, Yuqin Tan, Xiaofeng Liu, Chunfeng Zhang, Kunqi Su, Yang Jiang, Jianyuan Luo, Li Li, Xiaojuan Du
Summary: Cell fate during mitosis is controlled by spindle assembly. NAT10 regulates mitotic cell fate by acetylating Eg5, stabilizing its function and preventing mitotic catastrophe. The acetylation of Eg5 at K771 is essential for its motor function and centrosome localization during mitosis. Targeting NAT10-mediated Eg5 K771 acetylation may provide a potential strategy for tumor therapy.
CELL DEATH AND DIFFERENTIATION
(2022)
Article
Medical Laboratory Technology
Shanshan Zhang, Yajing Liu, Mingming Wang, Donata Ponikwicka-Tyszko, Wenqiang Ma, Anna Krentowska, Irina Kowalska, Ilpo Huhtaniemi, Slawomir Wolczynski, Nafis A. Rahman, Xiangdong Li
Summary: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, but its etiology and targeted therapy options are still unknown. The reduced expression of miR-335-5p in PCOS patients suggests its potential as a diagnostic biomarker and therapeutic target for PCOS. Further studies revealed the mechanistic pathway of miR-335-5p in the etiopathogenesis of PCOS, making it a promising candidate for further research and development.
TRANSLATIONAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros, Miguel-Angel Berciano-Guerrero, Alfonso Sanchez-Munoz, Maria Jose Lozano, Angela Farngren, Martina Alvarez, Beatriz Martinez-Galvez, Elisabeth Perez-Ruiz, Emilio Alba, Manuel Cobo, Antonio Rueda-Dominguez, Isabel Barragan
Summary: This pilot study aimed to evaluate the potential role of circRNA and lncRNA expression variability as a predictor of clinical response to immunotherapy in CMM patients. The findings showed that specific lncRNAs and circRNAs are involved in regulating the immune response in CMM patients under treatment with nivolumab, and a risk score model was established that accurately predicts the survival of CMM patients.
Review
Biology
Miguel-Angel Berciano-Guerrero, Mora Guardamagna, Elisabeth Perez-Ruiz, Jose-Miguel Jurado, Isabel Barragan, Antonio Rueda-Dominguez
Summary: Metastatic melanoma is a pathological entity with a poor prognosis, but new therapies have emerged in recent years. Targeted therapy and immunotherapy are the main treatment options for metastatic melanoma. However, the clinical progression and drug efficacy vary depending on the stage of diagnosis. Understanding the mechanisms and implications of targeted and immune therapies is crucial for optimizing diagnosis and treatment decisions.
Article
Biochemistry & Molecular Biology
Hongpeng Jiang, Yu Zhang, Boya Liu, Xin Yang, Zhe Wang, Meng Han, Huiying Li, Jianyuan Luo, Hongwei Yao
Summary: The acetylation of eEF1A1 is crucial for genotoxic stress response and maintaining the malignancy of colorectal cancer cells. Hyperacetylation of eEF1A1 at K439 promotes tumor progression by enhancing proliferation, migration, and invasion of CRC cells.
BIOLOGICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Runjie Song, Shuoqian Ma, Jiajia Xu, Xin Ren, Peilan Guo, Huijiao Liu, Peng Li, Fan Yin, Mei Liu, Qiang Wang, Lei Yu, Jiali Liu, Binwei Duan, Nafis A. Rahman, Slawomir Wolczynski, Guangming Li, Xiangdong Li
Summary: This study aims to elucidate the potential role and molecular mechanism of circZKSaa in the regulation of hepatocellular carcinoma (HCC) progression. Through a series of experiments, it was found that circZKSaa inhibited HCC progression and sensitized HCC cells to sorafenib. Furthermore, the high expression of cicZKSCAN1 in sorafenib-treated HCC cells was regulated by QKI-5. These findings demonstrate that circZKSaa has the potential to serve as a therapeutic target and biomarker for HCC treatment.
Article
Medical Laboratory Technology
Yajing Liu, Shanshan Zhang, Li Chen, Xuan Huang, Mingming Wang, Donata Ponikwicka-Tyszko, Nafis A. Rahman, Slawomir Wolczynski, Bing Yao, Xiangdong Li
Summary: The study found that miR-96-5p plays a crucial role in the pathogenesis of PCOS and may serve as a novel diagnostic biomarker and therapeutic target for PCOS.
TRANSLATIONAL RESEARCH
(2023)
Article
Chemistry, Multidisciplinary
Bingwei Wang, Miao Zhao, Zhijie Su, Baohua Jin, Xiaoning Yang, Chenyu Zhang, Bingbing Guo, Jiebo Li, Weili Hong, Jiarui Liu, Yun Zhao, Yujia Hou, Futing Lai, Wei Zhang, Lihua Qin, Weiguang Zhang, Jianyuan Luo, Ruimao Zheng
Summary: The RII beta subunit of cAMP-dependent protein kinase A (PKA) is expressed in the brain and adipose tissue. RII beta-knockout mice show leanness and increased UCP1 in brown adipose tissue. RII beta reexpression in hypothalamic GABAergic neurons rescues the leanness. The authors investigate the role of RII beta-PKA in white adipose tissue (WAT) browning and find that RII beta-KO mice exhibit robust WAT browning. They also demonstrate that RII beta-PKA in dorsal median hypothalamic GABAergic neurons regulates WAT browning and affects body weight. Targeting RII beta-PKA in DMH GABAergic neurons may have therapeutic potential for obesity and metabolic disorders.
Review
Oncology
Patricia Chaves, Maria Garrido, Javier Oliver, Elisabeth Perez-Ruiz, Isabel Barragan, Antonio Rueda-Dominguez
Summary: Head and neck cancer is the sixth most frequent cancer type, and the existing therapies face challenges of drug resistance and toxicity. Reliable preclinical models are crucial for studying molecular mechanisms and improving clinical outcomes. The most frequently used preclinical models for head and neck squamous cell carcinoma, including cell lines and animal models, are discussed in this review. Their efficiency in mimicking the complexity of the disease is evaluated, and the potential of the models for developing personalized therapies is explored.
BRITISH JOURNAL OF CANCER
(2023)
Article
Cell Biology
Shujuan Song, Zhenyi Su, Ning Kon, Bo Chu, Huan Li, Xuejun Jiang, Jianyuan Luo, Brent R. Stockwell, Wei Gu
Summary: ALOX5 plays a crucial role in mHTT-mediated ferroptosis, providing a new target for the treatment of Huntington's disease.
GENES & DEVELOPMENT
(2023)
Article
Cell Biology
Chen Song, Yu Zhang, Yutong Li, Juntao Bie, Zhe Wang, Xin Yang, Haishuang Li, Liangyi Zhu, Tianzhuo Zhang, Qing Chang, Jianyuan Luo
Summary: During interphase, the phosphorylation cascade of TrkA-ERK1/2-ABL1-PHF5A plays a critical role in regulating centrosome separation, which involves the disruption of the centrosome linker. The pY36-PHF5A enhances the interaction between CEP250 and Nek2A, leading to premature centrosome separation. This cascade is hyper-regulated in medulloblastoma and inhibiting it can restrict tumor proliferation.
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Runjie Song, Peilan Guo, Xin Ren, Lijun Zhou, Peng Li, Nafis A. Rahman, Slawomir Wolczynski, Xiru Li, Yanjun Zhang, Mei Liu, Jiali Liu, Xiangdong Li
Summary: This study reanalyzed the circRNA expression data of TNBC and identified circCAPG as a potential biomarker in TNBC. Further experiments showed that circCAPG could encode a novel polypeptide, CAPG-171aa, which promoted the proliferation and metastasis of TNBC cells. Additionally, SLU7 was found to be involved in the formation of circCAPG. These findings provide new insights into the role of circCAPG in TNBC and its potential as a therapeutic target and prognostic biomarker.
Article
Oncology
Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros, Manuel Cobo-Dols, Beatriz Martinez-Galvez, Ana Isabel Garcia-Pelicano, Jaime Dubbelman, Jose Carlos Benitez, Juan Zafra Martin, Alejandra Cantero, Elisabeth Perez-Ruiz, Antonio Rueda-Dominguez, Isabel Barragan
Summary: This study investigated the potential use of cfDNA quantification as a prognostic biomarker in NSCLC patients treated with ICB. The results showed that a cfDNA cut-off of 0.55 ng/μL before ICB treatment determines the overall survival of patients. High cfDNA concentrations indicate patients who do not benefit from ICB and may need alternative therapies.
